National Vision vs STAAR Surgical
EYE and STAA side by side, both in measuring, analyzing, and controlling instruments; photographic, medical and optical goods; watches and clocks. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EYE and STAA compare
National Vision and STAAR Surgical are about the same size, with market caps of $1.3B and $1.2B.
On earnings, National Vision is cheaper: it trades at 27.2× trailing earnings, against 351× for STAAR Surgical.
STAAR Surgical grew revenue faster over the last twelve months (51.3% versus 7.8% for National Vision).
National Vision keeps more of each dollar of sales as profit, with a net margin of 2.5% compared with 1.1% at STAAR Surgical.
National Vision scores higher on the StockData Score (13 against 10 for STAAR Surgical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EYE | STAA |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $1.2B |
| Share price | $16.59 | $24.54 |
| Change, 1 year | −38.6% | −7.7% |
| Change, 5 years | −74.5% | −78.8% |
| Beta (5Y) | 0.98 | 1.50 |
| Employees | 13K | 957 |
| StockData Score | ||
| Total score | 13 (better) | 10 |
| Valuation score | 6 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 27.2× (better) | 351× |
| P/S | 0.6× (better) | 3.6× |
| P/B | 1.5× (better) | 3.4× |
| EV/EBITDA | 8.6× (better) | 76.4× |
| P/FCF | 26.7× | – |
| FCF yield | 3.7% (better) | −0.55% |
| Fair value | $23.82 | $15.38 |
| Margin of safety | 30.4% (better) | −59.6% |
| Growth | ||
| Revenue growth (TTM) | 7.8% | 51.3% (better) |
| Revenue growth, 5Y average | 3.0% | 7.9% (better) |
| EPS growth, 5Y average | −3.4% | – |
| Profitability | ||
| Gross margin | 58.6% | 76.6% (better) |
| Operating margin | 4.1% (better) | 4.0% |
| Net margin | 2.5% (better) | 1.1% |
| FCF margin | 2.4% (better) | −2.0% |
| Return on equity | 5.8% (better) | 1.1% |
| Return on invested capital | 5.7% (better) | 4.2% |
| Financial health | ||
| Debt / equity | 0.26 (better) | 0.00 |
| Net debt / EBITDA | 1.11 | – |
| Current ratio | 0.59 | 4.66 (better) |
| Altman Z-score | 2.00 | 7.82 (better) |
| Piotroski F-score | 8 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 2.4% | – |
| Shareholder yield | 2.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 126% | 110% |
| Held by insiders | 2.5% | – |
| Insider net buying, 12 months | −$498K | $62.8M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 20.2% | – |
Go deeper
- EYE stock overview
- EYE income statement
- EYE valuation and score
- STAA stock overview
- STAA income statement
- STAA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.